Current Oncology Reports最新文献_第7页

Use of Circulating Tumor DNA to Guide Decision-making in Adjuvant Colon Cancer. 利用循环肿瘤 DNA 指导结肠癌辅助治疗决策。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-08-01 Epub Date: 2024-06-06 DOI: 10.1007/s11912-024-01565-y

Zachary Gottschalk, Stacey A Cohen

引用次数: 0

Immunological Checkpoint Blockade in Anal Squamous Cell Carcinoma: Dramatic Responses Tempered By Frequent Resistance. 肛门鳞状细胞癌的免疫检查点阻断疗法：频繁的抗药性抑制了剧烈的反应

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-08-01 Epub Date: 2024-06-11 DOI: 10.1007/s11912-024-01564-z

Thejus Jayakrishnan, Devvrat Yadav, Brandon M Huffman, James M Cleary

{"title":"Immunological Checkpoint Blockade in Anal Squamous Cell Carcinoma: Dramatic Responses Tempered By Frequent Resistance.","authors":"Thejus Jayakrishnan, Devvrat Yadav, Brandon M Huffman, James M Cleary","doi":"10.1007/s11912-024-01564-z","DOIUrl":"10.1007/s11912-024-01564-z","url":null,"abstract":"Purpose of review: Squamous cell carcinoma of the anus (SCCA) is an HPV-associated malignancy that has limited treatment options. Immunotherapy has expanded these options and here we review current and emerging immunotherapeutic approaches.Recent findings: Multiple studies of single-agent anti-PD1/PD-L1 immunotherapy have demonstrated a modest response rate of approximately 10% to 15%. While a minority of patients (~5%) with SCCA experience durable complete responses, most advanced SCCAs are resistant to anti-PD1/PD-L1 monotherapy. Given the need for more broadly effective immunotherapies, novel strategies, such as adaptive cell therapies and therapeutic vaccination, are being explored. To reduce the recurrence risk of localized high-risk SCCA, strategies combining immunotherapy with chemoradiation are also being investigated. While a small subset of patients with SCCA have prolonged responses to PD1-directed immunotherapy, the majority do not derive clinical benefit, and new immunotherapeutic strategies are needed. Better understanding of the immune microenvironment and predictive biomarkers could accelerate therapeutic advances.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success. BRAF 和 MEK 抑制剂的毒性：最大限度提高治疗成功率的策略。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-08-01 Epub Date: 2024-06-08 DOI: 10.1007/s11912-024-01544-3

Mike Wang, Ryan J Sullivan, Meghan J Mooradian

引用次数: 0

Telehealth Utilization in Neuro-Oncology: Commentary on a Single Institution Experience After the COVID-19 Pandemic. 远程医疗在神经肿瘤学中的应用：COVID-19 大流行后的单个机构经验评述。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-07-31 DOI: 10.1007/s11912-024-01588-5

Ugur Sener, Joon Uhm, Tufia Haddad, Joshua Pritchett

{"title":"Telehealth Utilization in Neuro-Oncology: Commentary on a Single Institution Experience After the COVID-19 Pandemic.","authors":"Ugur Sener, Joon Uhm, Tufia Haddad, Joshua Pritchett","doi":"10.1007/s11912-024-01588-5","DOIUrl":"https://doi.org/10.1007/s11912-024-01588-5","url":null,"abstract":"Purpose: During the COVID-19 pandemic, regulatory and reimbursement policy changes provided patients improved access to neuro-oncology by telehealth. Here we discuss benefits and limitations of telehealth use in neuro-oncology. We review utilization of telemedicine services following the COVID-19 pandemic.Recent findings: Utilization of telemedicine by neuro-oncology during the COVID-19 pandemic was 52%, compared to 27-29% for other solid tumors groups. Following the pandemic, between January 2021 and April 2024, telehealth utilization has remained high in neuro-oncology with approximately 30% of all visits completed by telemedicine, compared to 10-15% for other solid tumor groups. The striking difference between telehealth visit utilization in neuro-oncology and general medical oncology even after expiration of the COVID-19 Public Health Emergency expiration and end of pandemic-related restrictions, underscores the potential value of convenient access to care for patients with central nervous system tumors. Given widespread use of telehealth in neuro-oncology, prospective evaluation to determine the safety, usability, and acceptance of video-enabled, telehealth visits is critical. Such data may lead to broader adoption of telehealth, lead to regulatory and reimbursement reform for telehealth sustainability, and improve clinical trial access and accruals.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the Role of Target Expression in Treatment Efficacy of Antibody–Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review 探索靶点表达在抗体药物结合物 (ADC) 治疗实体癌疗效中的作用：全面综述

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-07-27 DOI: 10.1007/s11912-024-01576-9

Laurent Mathiot, Capucine Baldini, Octave Letissier, Antoine Hollebecque, Rastislav Bahleda, Anas Gazzah, Cristina Smolenschi, Madona Sakkal, François-Xavier Danlos, Clémence Henon, Kristi Beshiri, Vincent Goldschmidt, Claudia Parisi, Anna Patrikidou, Jean-Marie Michot, Aurélien Marabelle, Sophie Postel-Vinay, Alice Bernard-Tessier, Yohann Loriot, Santiago Ponce, Stéphane Champiat, Kaïssa Ouali

{"title":"Exploring the Role of Target Expression in Treatment Efficacy of Antibody–Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review","authors":"Laurent Mathiot, Capucine Baldini, Octave Letissier, Antoine Hollebecque, Rastislav Bahleda, Anas Gazzah, Cristina Smolenschi, Madona Sakkal, François-Xavier Danlos, Clémence Henon, Kristi Beshiri, Vincent Goldschmidt, Claudia Parisi, Anna Patrikidou, Jean-Marie Michot, Aurélien Marabelle, Sophie Postel-Vinay, Alice Bernard-Tessier, Yohann Loriot, Santiago Ponce, Stéphane Champiat, Kaïssa Ouali","doi":"10.1007/s11912-024-01576-9","DOIUrl":"https://doi.org/10.1007/s11912-024-01576-9","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3>Antibody–drug conjugates (ADCs) offer a promising path for cancer therapy, leveraging the specificity of monoclonal antibodies and the cytotoxicity of linked drugs. The success of ADCs hinges on precise targeting of cancer cells based on protein expression levels. This review explores the relationship between target protein expression and ADC efficacy in solid tumours, focusing on results of clinical trials conducted between January 2019 and May 2023.<h3 data-test=\"abstract-sub-heading\">Recent Findings</h3>We hereby highlight approved ADCs, revealing their effectiveness even in low-expressing target populations. Assessing target expression poses challenges, owing to variations in scoring systems and biopsy types. Emerging methods, like digital image analysis, aim to standardize assessment. The complexity of ADC pharmacokinetics, tumour dynamics, and off-target effects emphasises the need for a balanced approach.<h3 data-test=\"abstract-sub-heading\">Summary</h3>This review underscores the importance of understanding target protein dynamics and promoting standardized evaluation methods in shaping the future of ADC-based cancer therapies.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141772108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

For the Long Haul: Management of Long-Term Survivors after Melanoma Systemic Therapy. 为了长远：黑色素瘤系统治疗后长期存活者的管理。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-07-01 Epub Date: 2024-05-23 DOI: 10.1007/s11912-024-01541-6

Jordyn Silverstein, Neha Goyal, Katy K Tsai

{"title":"For the Long Haul: Management of Long-Term Survivors after Melanoma Systemic Therapy.","authors":"Jordyn Silverstein, Neha Goyal, Katy K Tsai","doi":"10.1007/s11912-024-01541-6","DOIUrl":"10.1007/s11912-024-01541-6","url":null,"abstract":"Purpose of review: This review summarizes the latest advancements in survivorship care for patients with advanced melanoma who received systemic therapy and emphasizes the areas where more research is needed.Recent findings: Over the last decade there have been remarkable advances in the treatment of advanced and metastatic melanoma. Due to these novel treatments, including several immune checkpoint inhibitors and tyrosine kinase inhibitors, there are and will continue to be increasing numbers of long-term melanoma survivors who have been treated with systemic therapy. These patients will navigate new challenges are they are essentially among the first long term survivors after these novel therapies. Survivorship care focuses on improving the health-related quality of life of patients including the physical, emotional, social and functional effects of cancer that begin at diagnosis and continue through the end of life. Survivorship also includes screening for cancer recurrence and second cancers. As the number of melanoma survivors who received systemic therapy continues to grow, the survivorship care plan will become increasingly important for optimal care of patients even after their cancer treatments. Understanding the many domains of survivorship care for this group of patients is imperative for their care now and to identify unmet needs for future research.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141080733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond Immune Checkpoint Inhibitors: Emerging Targets in Melanoma Therapy. 超越免疫检查点抑制剂：黑色素瘤治疗中的新靶点。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-07-01 Epub Date: 2024-05-25 DOI: 10.1007/s11912-024-01551-4

Andrew D Knight, Jason J Luke

引用次数: 0

Axillary Management: How Much Is Too Much? 腋窝管理：多少才算多？

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-07-01 Epub Date: 2024-05-15 DOI: 10.1007/s11912-024-01539-0

Nicci Owusu-Brackett, Benjin Facer, Dionisia Quiroga, Ashley Pariser, Michael Grimm, Sasha Beyer, Sachin Jhawar, Bridget A Oppong

引用次数: 0

Anamorelin for the Treatment of Cancer Anorexia-Cachexia Syndrome. 阿那莫林治疗癌症厌食-痛风综合征。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-07-01 Epub Date: 2024-05-21 DOI: 10.1007/s11912-024-01549-y

Rony Dev, Koji Amano, Tateaki Naito, Egidio Del Fabbro

{"title":"Anamorelin for the Treatment of Cancer Anorexia-Cachexia Syndrome.","authors":"Rony Dev, Koji Amano, Tateaki Naito, Egidio Del Fabbro","doi":"10.1007/s11912-024-01549-y","DOIUrl":"10.1007/s11912-024-01549-y","url":null,"abstract":"Purpose of review: The following review will highlight the development of anamorelin to treat cancer anorexia-cachexia syndrome (CACS) including the potential benefits, limitations, and future directions.Recent findings: Ghrelin, a 28-amino acid peptide hormone, is secreted by the stomach mucosa and regulates appetite, promotes lipogenesis, increases body weight, improves gastric motility, reduces catabolic wasting and inflammation. Several randomized, double-blind, placebo-controlled clinical trials evaluating anamorelin, a ghrelin agonist, for the treatment of CACS have reported improvement in appetite and body composition including both lean body and fat mass; however, most studies noted no improvement in physical function as assessed by measuring non-dominant hand-grip strength. Common adverse effects of anamorelin include the development of diabetes mellitus, hyperglycemia, and less frequently, hepatic abnormalities and cardiovascular events including conduction abnormalities, hypertension, and ischemic cardiomyopathy. Anamorelin has the potential to stimulate appetite, improve gastric movement, and may have anti-inflammatory effects on patients with CACS. In patients with cancer, studies involving anamorelin combined with other multimodal treatments including nutrition counseling (branched chain amino acids, omega 3 fatty acids, and other nutrients), exercise, treatment of hormonal abnormalities including hypogonadism and hypovitaminosis D, and anti-inflammatory agents are needed. Compliance with multimodality treatment has been a barrier and future studies may need to incorporate motivational counseling to promote adherence.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141069991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancements in the Management of Synchronous Colorectal Liver Metastases: A Comprehensive Review of Surgical, Systemic, and Local Treatment Modalities. 同步性结直肠癌肝转移的治疗进展：手术、系统和局部治疗模式的全面回顾。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-07-01 Epub Date: 2024-05-22 DOI: 10.1007/s11912-024-01548-z

Beliz Bahar Karaoğlan, Diğdem Kuru Öz, Mine Soylu Araz, Cihangir Akyol, Güngör Utkan

{"title":"Advancements in the Management of Synchronous Colorectal Liver Metastases: A Comprehensive Review of Surgical, Systemic, and Local Treatment Modalities.","authors":"Beliz Bahar Karaoğlan, Diğdem Kuru Öz, Mine Soylu Araz, Cihangir Akyol, Güngör Utkan","doi":"10.1007/s11912-024-01548-z","DOIUrl":"10.1007/s11912-024-01548-z","url":null,"abstract":"Purpose of review: This review addresses the current landscape of colorectal cancer (CRC) with a focus on liver metastases, the third most common cancer globally. It explores recent findings in treatment strategies, emphasizing the dynamic interplay between surgery, systemic chemotherapy, and local therapies for synchronous colorectal liver metastases (CRLMs).Recent findings: Highlighting the role of advanced imaging, the review underscores the significance of contrast-enhanced MRI in surgical planning for CRLMs. Surgical resection remains a primary choice for resectable cases, with considerations for oncologic scoring systems and tumor biology. Perioperative systemic chemotherapy plays a pivotal role, especially in conversion therapy for initially unresectable CRLMs. The review also explores various local therapies, including radiofrequency ablation, microwave ablation, stereotactic body radiotherapy, hepatic arterial infusional chemotherapy, selective internal radiation therapy, and transarterial chemoembolization for unresectable cases. A comprehensive approach, integrating surgery, systemic chemotherapy, and local therapies, is crucial for managing synchronous CRLMs. Surgical resection and perioperative chemotherapy are key players, guided by considerations of tumor biology and scoring systems. For unresectable cases, local therapies offer viable alternatives, emphasizing the need for tailored treatments. Multidisciplinary collaboration among medical oncologists, surgeons, and radiologists is essential. Ongoing research will refine treatment approaches, while emerging technologies hold promise for further advancements in managing colorectal liver metastases.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11224077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141075498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0